Key result
Carvedilol treatment in moderate heart failure blunted sympathetic hyperactivity, reducing the LF/HF ratio compared to controls (7.0 vs 10.4; P<0.05) and baseline (4.9 vs 7.9; P<0.05).
Why the study?
Does carvedilol improve autonomic tone and responsiveness in patients with moderate heart failure?
Observational (n=70)
Does carvedilol improve autonomic tone and responsiveness in patients with moderate heart failure?
Absolute Event Rate: 7% vs 10.4%
p-value: p=<0.05
Long-term treatment with carvedilol in moderate heart failure reduces sympathetic hyperactivity and restores autonomic responsiveness, which may contribute to its favorable clinical effects.
No takes yet. Share an insight, caveat, or question.
May blunt sympathetic drive in moderate HF; hypothesis-generating and requires randomized confirmation before practice change.
Malfatto et al. (2003) conducted an observational in Moderate Heart Failure (n=70). Carvedilol vs. Patients not receiving carvedilol (Study 1) or baseline before treatment (Study 2) was evaluated on Sympathovagal interaction (LF/HF ratio of RR variability) (p=<0.05). Carvedilol treatment in moderate heart failure blunted sympathetic hyperactivity, reducing the LF/HF ratio compared to controls (7.0 vs 10.4; P<0.05) and baseline (4.9 vs 7.9; P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: